* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download The role of coronary microvascular disorder in congestive heart failure
Survey
Document related concepts
Baker Heart and Diabetes Institute wikipedia , lookup
Cardiovascular disease wikipedia , lookup
Saturated fat and cardiovascular disease wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Electrocardiography wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
History of invasive and interventional cardiology wikipedia , lookup
Rheumatic fever wikipedia , lookup
Heart failure wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
Transcript
Am J Physiol Heart Circ Physiol 308: H814–H815, 2015; doi:10.1152/ajpheart.00118.2015. Editorial Focus The role of coronary microvascular disorder in congestive heart failure Georges E. Haddad, Sana Chams, and Nour Chams Department of Physiology and Biophysics, College of Medicine, Howard University, Washington, District of Columbia Address for reprint requests and other correspondence: G. E. Haddad, Dept. Physiology and Biophysics, College of Medicine, Howard Univ., 520 W. St. NW, Washington, DC 20059 (e-mail: [email protected]). H814 play(s) a key role in the development of heart failure: myocytes, extracellular matrix, and/or vasculature? Coronary arterial disease is a main cause of heart failure. But most published research and techniques have been focusing on coronary arterial main branches, and only recently has microvascular dysfunction been getting more attention (6, 14, 16). Coronary microvascular dysfunction was observed in patients with hypertrophic cardiomyopathy. But its detailed role in heart failure is not very clear because accurate quantitative assessment of microvascular function and myocardial ischemia is not easily feasible in clinical practice and bench research, especially in rodents (1, 12). Microvascular obstruction, index of microcirculatory resistance, and hyperemic microvascular resistance were widely used parameters to identify microcirculation dysfunction. Invasive methods were based on principle of thermodilution or Doppler flow with guide wires (1), whereas noninvasive positron emission tomography (PET) served as a gold standard for noninvasive assay of myocardial blood flow (5, 11). However, there is no solid proof to directly correlate coronary microvascular dysfunction to ischemic heart failure in vivo in human patients and animals to date, which is probably due to the lack of proper model and the need for more advanced finer techniques. In this current issue of the American Journal of PhysiologyHeart and Circulatory Physiology, Chen and colleagues (8) reported their serial studies on coronary arterial disorder in congestive CHF in rats. The authors showed successive vascular changes of coronary arteries from main, middle, and small arterial branches to arterioles and capillaries in the CHF model. Heart failure was induced by chronic aortic constriction with ischemia-reperfusion followed by aortic debanding. Their main hypothesis is that the development of heart failure is associated with vascular disorders that occur in not only main branches of the coronary artery but also arterioles and capillaries. The capillary structural disorders found in CHF hearts were diverse to include stenosis, nonlinear arrangement, curled shape, drastic changes in diameter, proliferation, and roughened surface texture. Capillary disorder can be one of the critical contributing factors to the energy starvation that leads to the reduction of intrinsic contractile properties of the underlying myocytes. However, it is still a big challenge to simultaneously assess myocardial contractility and microvascular blood flow in rodent animals. Future studies on the role of coronary microcirculation disorder (CMD) in CHF should involve the assessment of 1) the correlation between the degree and range of CMD and heart failure, specifically, the impact of the regional CMD on the global cardiac pumping function of the heart (contractility) by using invasive and noninvasive techniques; 2) the relationship between narrowing (atherosclerotic) of the main arteries and the impact on distal and proximal capillary disorders, which assess the importance of the global coronary blood flow reserve to the regional blood flow disorder, as well as to microvascular and endothelial dysfunction; and 3) an evaluation of the impact 0363-6135/15 Copyright © 2015 the American Physiological Society http://www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.246 on May 2, 2017 heart failure are coronary heart disease (coronary artery atherosclerosis), hypertension, cardiomyopathy, and heart valve disease (4). Accordingly, the most common models of heart failure are coronary arterial occlusion, temporally (partially) or permanently (completely); aortic constriction or high-salt feeding; gene-deficient and knockout models; and mitral, aortic regurgitation (10). Each model of heart failure has its pros and cons versus the respective human condition. Left anterior descending artery ligation is the most widely used model; however, in the myocardial infarction model, distal myocardial tissue to the occlusion site was almost normal, especially in rodent animals, even a couple of months postocclusion (7). Aortic constriction offers a good model for myocyte hypertrophy in mice, rats, swine, and dogs. However, the occurrence of congestive heart failure (CHF) post-aortic constriction depends on the degree of aortic stenosis and the overload duration (3). Left ventricle function could be preserved up to 4 mo post-aortic banding (even with 72% aortic constriction) with collagen fiber accumulation in the interstitial and perivascular space (7). Despite that, gene-deficient and knockout rodent models were globally used in heart failure research, and no individual gene-deficient and knockout models could bring a breakthrough in the treatment of heart failure, probably because of a simple reason: heart failure is not a disease induced by monogene/protein (4). Advances in heart failure treatment have been mostly achieved in surgical progress, like coronary artery stents, bypass, heart assistant devices, or heart transplantation. However, limitations associated with angioplasty and stent have been the restenosis that can occur within 6 mo after the initial procedure. The chance of restenosis is from 25 to 40% (9). Heart failure research in pharmacological management has been largely dispirited. There have been many advances in studying myocyte contractility, but inotropic agents just could not improve cardiac dysfunction. The fibrosis inhibitors such as the angiotensin-converting enzyme inhibitor, like candesartan (15) and irbesartan, did not show a beneficial effect in a patient with CHF (13, 18). To date, there is no single drug regimen that could effectively reverse cardiac dysfunction. Despite the fact that gene therapy and stem cells therapy offer great promise for heart failure treatment, uncertainties and controversies still remain, including the high-yield transgene expression/stem cell implantation in the heart and long-term utility. In that regard, the obvious question is, What type of cells can be regenerated to strengthen cardiac performance: myocytes or endothelial cells (capillaries)? Do the regenerated cells or repaired LV part (ischemic area or remote area) play a key role in the overall progression of the heart failure and to what extent (2, 17)? This largely addresses our predicament in understanding heart failure: Which cardiac component(s) COMMON CAUSES OF Editorial Focus H815 of novel therapies, such as AAV.VEGFa transgene, stem cell therapies, and antiangina (ivabradine and ranolazine) therapies. 9. GRANTS This work was supported in part by Research Centers in Minority Institutions Division of Research Infrastructure Grants 1 R15 AA019816-01A1 and 8 G12MD007597. 10. DISCLOSURES No conflicts of interest, financial or otherwise, are declared by the author(s). 11. G.E.H. conception and design of research; G.E.H. and S.C. analyzed data; G.E.H., S.C., and N.C. interpreted results of experiments; G.E.H., S.C., and N.C. drafted manuscript; G.E.H., S.C., and N.C. edited and revised manuscript; G.E.H. approved final version of manuscript. 12. REFERENCES 13. 1. Amier RP, Teunissen PF, Marques KM, Knaapen P, van Royen N. Invasive measurement of coronary microvascular resistance in patients with acute myocardial infarction treated by primary PCI. Heart 100: 13-20, 2014. 2. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 61: 2329 –2338, 2013. 3. Boluyt MO, Robinson KG, Meredith AL, Sen S, Lakatta EG, Crow MT, Brooks WW, Conrad CH, Bing OH. Heart failure after long-term supravalvular aortic constriction in rats. Am J Hypertens 18: 202–212, 2005. 4. Braunwald E. Heart failure. JACC Heart fail 1: 1–20, 2013. 5. Camici PG. Advances in SPECT and PET for the management of heart failure. Heart 96: 1932–1937, 2010. 6. Cecchi F, Sgalambro A, Baldi M, Sotgia B, Antoniucci D, Camici PG, Sciagra R, Olivotto I. Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2: 452–461, 2009. 7. Chen J, Chemaly ER, Liang LF, LaRocca TJ, Yaniz-Galende E, Hajjar RJ. A new model of congestive heart failure in rats. Am J Physiol Heart Circ Physiol 301: H994 –H1003, 2011. 8. Chen J, Yaniz-Galende E, Kagan HJ, Liang L, Hekmaty S, Giannarelli C, Hajjar RJ. Abnormalities of capillary microarchitecture in a 14. 15. 16. 17. 18. AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00118.2015 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.32.246 on May 2, 2017 AUTHOR CONTRIBUTIONS rat model of coronary ischemic congestive heart failure. Am J Physiol Heart Circ Physiol 308: 2015. doi:10.1152/ajpheart.00583.2014. Dangas G, Kuepper F. Cardiology patient page. Restenosis: repeat narrowing of a coronary artery: prevention and treatment. Circulation 105: 2586 –2587, 2002. Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, Prabhu SD, Rockman HA, Kass DA, Molkentin JD, Sussman MA, Koch WJ; American Heart Association Council on Basic Cardiovascular Sciences, Council on Clinical Cardiology, and Council on Functional Genomics and Translational Biology. Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res 111: 131–150, 2012. Kaufmann PA, Camici PG. Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med 46: 75–88, 2005. Koudstaal S, Jansen Of Lorkeers SJ, van Slochteren FJ, van der Spoel TI, van de Hoef TP, Sluijter JP, Siebes M, Doevendans PA, Piek JJ, Chamuleau SA. Assessment of coronary microvascular resistance in the chronic infarcted pig heart. J Cell Mol Med 17: 1128 –1135, 2013. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, Investigators IP. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359: 2456 –2467, 2008. Olivotto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM, Nistri S, Sgalambro A, Grifoni C, Torricelli F, Camici PG, Cecchi F. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 58: 839 –848, 2011. Onishi K, Dohi K, Koji T, Funabiki K, Kitamura T, Imanaka-Yoshida K, Ito M, Nobori T, Nakano T. Candesartan prevents myocardial fibrosis during progression of congestive heart failure. J Cardiovasc Pharmacol 43: 860 –867, 2004. Petersen JW, Pepine CJ. Microvascular coronary dysfunction and ischemic heart disease: Where are we in 2014? Trends in cardiovascular medicine, 2014. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM, Investigators RA. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 27: 2775–2783, 2006. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Investigators C, Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777–781, 2003.